We subsequently tested the inhibitory effectiveness of anlotinib in various KRAS-mutant NSCLC cell lines, including G12C, G12D, G12S, G12V, and Q61H, in vitro. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.